Norway· NO-ID_84D3FCC7-6C64-4B2A-B287-00AB6E4422C6
Myalepta
A metreleptin product containing metreleptin, registered in Norway by Chiesi Farmaceutici S.p.a.. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Metreleptin is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AA07 (metreleptin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Metreleptin · ATC A16AA07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Metreleptin
- Manufacturer
- Chiesi Farmaceutici S.p.a.
- Country
- Norway (NO)
- ATC code
- A16AA07
- ATC class
- Metreleptin
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- gtin5397203001244
- no_merkevare_idID_84D3FCC7-6C64-4B2A-B287-00AB6E4422C6
- no_varenummer53573230 x 3NOK 207933.4
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
193 interactions on record for metreleptin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metreleptin · interactions on record
193 records
- 1 severe
- 188 moderate
- 4 minor
Most severe, free to view
- RolapitantA04AD14moderate
- NaloxegolA06AH03moderate
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Metreleptin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMYALEPTAChiesi Farmaceutici S.p.A., Parma
- SpainMYALEPTA 3 MG POLVO PARA SOLUCION INYECTABLEChiesi Farmaceutici S.P.A.
- BelgiumMyalepta 3 mgChiesi Farmaceutici
- IcelandMyaleptaChiesi Farmaceutici S.p.A.*
- PolandMyaleptaChiesi Farmaceutici S.p.A.
- SwedenMyalepta 3 mg Pulver till injektionsvätska, lösningChiesi Farmaceutici S.p.A.
- United KingdomMyalepta 3mg powder for solution for injection vialsChiesi Ltd
- FinlandMyaleptaChiesi Farmaceutici S.p.A.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Myalepta
- Liechtenstein · Myalepta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/edd4c0a1-86ef-4198-a664-e52eeff0e6b3 GET /v1/drugs/edd4c0a1-86ef-4198-a664-e52eeff0e6b3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Metreleptin",
"merkevare_id": "ID_84D3FCC7-6C64-4B2A-B287-00AB6E4422C6",
"name_form_strength": "Myalepta pulv til inj væske, oppl 3 mg",
"prescription_group": "C"
}See everything about metreleptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.